The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.
 
Solmaz Sahebjam
Research Funding - Bristol-Myers Squibb; Cortice Biosciences; Merck
 
Shakti Ramkissoon
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Research Funding - Bristol-Myers Squibb
 
Joachim M. Baehring
No Relationships to Disclose
 
Paul James Mulholland
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Oliver M. Grauer
Honoraria - Medac; Roche
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Magforce
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); midatech (Inst); Tragara (Inst)
 
Michael Lim
Honoraria - Agenus; Bristol-Myers Squibb; Merck; Oncorus
Consulting or Advisory Role - Agenus; Bristol-Myers Squibb; Merck; Oncorus
Research Funding - Accuray; Agenus; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Johns Hopkins University
Travel, Accommodations, Expenses - Agenus; Bristol-Myers Squibb; Merck; Oncorus
 
Ricardo F. Zwirtes
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert Raymond Latek
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Lewis C. Strauss
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Keith L. Ligon
Consulting or Advisory Role - Midatech
Research Funding - Plexxikon
Patents, Royalties, Other Intellectual Property - Molecular Diagnostics Assay Patent